Analysis of biomarkers in the diagnostic of bladder cancer recurrence.

• Grant number: 16/07917-5
• Support Opportunities: Regular Research Grants
• Start date: September 01, 2016
• End date: August 31, 2018
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: William Carlos Nahas
• Grantee: William Carlos Nahas
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Kátia Ramos Moreira Leite ; Miguel Srougi ; Sabrina Thalita dos Reis Faria ; Victor Srougi

Abstract

Introduction: Bladder cancer is the forth most common neoplasia among men and is associated with a high recurrence chance, up to 70% in five years. Moreover, this tumor has a high mortality rate, between 30 and 70% according to the disease stage. Therefore, the follow-up for bladder cancer must be strict and continuous, comprising expensive and invasive exams. Because of this intense regimen of follow-up and the need for aggressive treatments, this tumor is one of the most expensive neoplasias to treat. Thus, it would be valuable to develop a new monitoring exam, less invasive and cheaper, that also could spare the patients from the inconvenient of invasive exams. In this way, efforts are being made to develop an efficient urine biomarker that could predict recurrence and prognosis of patients affected by bladder cancer. In the present study, we aim to evaluate the association between the secretion of eight different proteins in the urine of patients on follow-up for bladder cancer and the chance of tumor recurrence.Patients and Methods: Two hundred patients previously treated of bladder cancer and currently on follow-up regimen will be included. The subjects of this research will be selected from the ambulatory of the "Instituto do Câncer do Estado de São Paulo". Their urine will be collected during an ambulatory visit and send to be analyzed by ELISA. Primary endpoint is the correlation of eight proteins (MMP-9*, IL-8*, PAI-1*, APOA4*, coronin-1A, seminogelin-2, ³-synuclein and DJ-1) quantitative excretion in the urine and the chance of bladder cancer recurrence. Secondary endpoints are the association between eight proteins quantitative excretion in the urine with prognosis and anticipatory role for tumor recurrence. Minimal follow-up will be 2 years. A control group will comprise 50 healthy individuals, free from urological disorders or other known tumors. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SROUGI, VICTOR; REIS, SABRINA T.; VIANA, NAYARA; GALLUCCI, FABIO P.; LEITE, KATIA R.; SROUGI, MIGUEL; NAHAS, WILLIAM C.. Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer. World Journal of Urology, v. 39, n. 2, SI, APR 2020. (16/07917-5)

SROUGI, VICTOR; REIS, SABRINA T.; VIANA, NAYARA; GALLUCCI, FABIO P.; LEITE, KATIA R.; SROUGI, MIGUEL; NAHAS, WILLIAM C.. Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer. World Journal of Urology, v. 39, n. 2, p. 7-pg., 2020-04-06. (16/07917-5)